A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.

A method of making coated avian egg yolk cores includes providing dried avian egg yolk cores having a diameter of 100 to 1500 micrometers, applying avian egg albumen to the dried avian egg yolk cores to provide the coated avian egg yolk cores, and optionally drying the coated avian egg yolk cores, wherein the ratio of dry avian egg albumen to dried avian egg yolk in the coated avian egg yolk cores is 1:10 to 10:1. Also included are the coated avian egg yolk cores, food and feed additives containing the coated avian egg yolk cores and food and feed compositions containing the coated avian egg yolk cores.

The present disclosure provides a composition and a method both for improving the hair. In one embodiment, the hair is improved using an antibody. In one embodiment, the antibody is produced using a bacterium occurring on the scalp or a hair root as an immunogen. In one aspect, the present invention also provides a method for improving the hair in a subject, including the step of administering an antibody produced using a microorganism-derived substance as an immunogen to the subject. The antibody according to the present invention may be administered in the form of a composition. According to the present invention, the promotion of hair growth or the prevention of hair loss can be achieved.

The present disclosure provides a composition and a method both for improving the hair. In one embodiment, the hair is improved using an antibody. In one embodiment, the antibody is produced using a bacterium occurring on the scalp or a hair root as an immunogen. In one aspect, the present invention also provides a method for improving the hair in a subject, including the step of administering an antibody produced using a microorganism-derived substance as an immunogen to the subject. The antibody according to the present invention may be administered in the form of a composition. According to the present invention, the promotion of hair growth or the prevention of hair loss can be achieved.

The present disclosure relates to a fast and simple process for the obtention of high purity immunoglobulins (Igs) or antibodies. These polyclonal antibodies are obtained from egg yolk, representing an alternative way for the acquisition thereof and a renewable and profitable source for the production thereof.

The process described herein encompasses several steps in which low cost, biocompatible and selective precipitating agents can be used in conjunction with an ultrafiltration step.

The present disclosure relates to a fast and simple process for the obtention of high purity immunoglobulins (Igs) or antibodies. These polyclonal antibodies are obtained from egg yolk, representing an alternative way for the acquisition thereof and a renewable and profitable source for the production thereof.

The process described herein encompasses several steps in which low cost, biocompatible and selective precipitating agents can be used in conjunction with an ultrafiltration step.

This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.

This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.

A composition for treatment of mucosal infection in an animal by application to a mucous membrane includes a mixture of IgY antibodies specific for a plurality of antigens obtained from a plurality of organisms, with the plurality of organisms able to cause infection of the mucous membrane. A protective matrix including non-hyperimmune colostrum can be combined with the mixture of IgY antibodies, with the protective matrix forming at least 20% by weight of the composition.

The composition may be used therapeutically or prophylactically and is directed toward a cluster of diarrhea-causing pathogens which cause illness or death in animals, including dogs and cats. It is prepared from a powdered egg preparation and powdered protein matrix, such as bovine colostrum. The eggs are collected from hens which have been immunized with the relevant pathogens or toxins. When the matrix includes colostrum, the powdered colostrum is derived from non-hyperimmune cattle. The vaccination strategy includes the use of antibody cross-reactivity between toxins or pathogens which cause diarrhea. For some diseases, including canine parvo, the clinical improvement using this therapeutic exceeds the standard of care. Instead of a pharmaceutical product, this composition is an orally administered food product with the same safety profile as eggs and milk.